Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting

by Vandana Singh, Benzinga Editor

October 18, 2021 12:12 PM | 1 min read |

The FDA has greenlit Roche Holdings AG's RHHBY Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with the expression of the PD-L1 biomarker covering at least 1% of tumor cells.
Related: After Bladder Cancer, Roche Pulls Breast Cancer Indication For Tecentriq In US.
The agency based its review on data from the Phase 3 IMpower010 study, which showed adjuvant Tecentriq cut the risk of relapse or death by 34% over best supportive care.
Related content: Benzinga's Full FDA Calendar.
Price Action: RHHBY shares are up 0.45% at $49.14 during the market session on the last check Monday.

Posted In: Biotech News Health Care FDA General Briefs Non-Small Cell Lung Cancer

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.